Oragenics Inc (NYSEAMERICAN:OGEN) shares were up 6% during mid-day trading on Thursday . The company traded as high as $0.89 and last traded at $0.89. Approximately 1,082,528 shares changed hands during trading, a decline of 5% from the average daily volume of 1,134,611 shares. The stock had previously closed at $0.84.
Hedge funds have recently made changes to their positions in the business. Barclays PLC lifted its holdings in Oragenics by 95.9% in the fourth quarter. Barclays PLC now owns 135,400 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 66,275 shares during the period. Virtu Financial LLC lifted its holdings in Oragenics by 297.9% in the fourth quarter. Virtu Financial LLC now owns 138,233 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 103,496 shares during the period. Finally, BlackRock Inc. lifted its holdings in Oragenics by 82,549.2% in the fourth quarter. BlackRock Inc. now owns 705,824 shares of the biotechnology company’s stock worth $606,000 after purchasing an additional 704,970 shares during the period.
TRADEMARK VIOLATION WARNING: This report was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.com-unik.info/2019/03/14/oragenics-ogen-shares-up-6.html.
Oragenics, Inc focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.
Recommended Story: Understanding the different types of bonds
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.